Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • lws2000 lws2000 May 8, 2013 9:41 PM Flag

    Hope and Speculation for Geron

    "The compelling proof-of-concept data from our trial of imetelstat in ET and the progress made in the current myelofibrosis study at Mayo Clinic support Geron`s focus on the development of imetelstat in hematologic myeloid malignancies.Diseases such as myelofibrosis represent the greatest value-creating opportunity for the company because many patients with these diseases have significant unmet medical needs and imetelstat has the potential to be a disease-modifying treatment," said John A. Scarlett, M.D., Geron`s President and Chief Executive Officer. "The actions announced today allow us to concentrate our financial and operational resources solely on this development strategy."

 
GERN
3.05+0.12(+4.10%)Sep 2 4:00 PMEDT